

		EMLc	ATC codes: <a href="#">L01CA04</a>
Indication	Rhabdomyosarcoma primary site	ICD11 code: <a href="#">2C25.Z</a>	
INN	Vinorelbine		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 10 mg per mL in 1 mL vial ; 10 mg per mL in 5 mL vial Oral > Solid > capsule: 20 mg ; 30 mg ; 80 mg (EML)		
EML status history	First added in 2021 ( <a href="#">TRS 1035</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Vinorelbine</a> 		
DrugBank	<a href="#">Vinorelbine</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended deletion of vinorelbine 80 mg capsules from the EMLc, and modification of the description of the parenteral forms on the EML and EMLc to 10 mg/mL in 1 mL and 5 mL vials.

